Vir Biotechnology, Inc. (VIR)
Vir Biotechnology, Inc. (VIR)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| In-process research and development impairment | NaN | 0 | 0 | 0 |
| Net loss | -125,695 | -42,923 | -163,141 | -231,923 |
| Depreciation and amortization | 2,811 | 2,898 | 2,998 | 5,784 |
| Amortization of premiums on investments, net | -394 | -1,549 | -1,315 | -6,610 |
| Noncash lease expense | 1,338 | 1,325 | 1,297 | 2,358 |
| Payment of contingent consideration in excess of acquisition date fair value | NaN | 0 | 0 | -17,140 |
| Non-cash restructuring, long-lived assets impairment and related charges | NaN | 255 | 0 | 399 |
| Change in fair value of equity investments | 170 | 2,606 | -1,335 | -3,000 |
| Change in estimated fair value of contingent consideration | -890 | -80 | 560 | 11,010 |
| Stock-based compensation | 12,087 | 11,206 | 11,356 | 26,510 |
| Other non-cash items, net | 82 | 132 | -19 | 59 |
| Prepaid expenses and other current assets | -382 | 8,077 | -4,215 | -5,937 |
| Other assets | -657 | 8,718 | 2,792 | 1,132 |
| Deferred revenue | NaN | NaN | -675 | -2,540 |
| Accounts payable | -4,226 | 2,955 | -5,402 | 7,444 |
| Accrued liabilities and other long-term liabilities | -17,223 | 10,104 | -14,155 | -5,458 |
| Operating lease liabilities | -2,273 | -2,323 | -1,792 | -3,253 |
| Net cash used in operating activities | -132,386 | -25,876 | -167,570 | -198,335 |
| Proceeds from sale of equipment | 0 | -110 | 37 | 326 |
| Purchases of long-lived assets | 390 | 348 | 317 | 4,167 |
| Purchases of investments | 158,374 | 255,822 | 264,447 | 366,065 |
| Maturities and sales of investments | 170,599 | 342,931 | 305,173 | 553,180 |
| Net cash provided by investing activities | 11,835 | 86,651 | 40,446 | 183,274 |
| Proceeds from issuance of common stock under espp | NaN | 1,040 | 0 | 1,757 |
| Proceeds from exercise of stock options | 174 | 1 | 101 | 1,247 |
| Other financing activities | NaN | -2 | 1 | -360 |
| Issuance of common stock in connection with a follow-on public offering, net of issuance cost | 162,349 | NaN | NaN | NaN |
| Net cash provided by financing activities | 162,523 | 1,039 | 102 | 2,644 |
| Net increase in cash, cash equivalents and restricted cash and cash equivalents | 41,972 | 61,814 | -127,022 | -12,417 |
| Cash, cash equivalents and restricted cash and cash equivalents at beginning of period | 241,070 | 179,256 | 318,695 | NaN |
| Cash, cash equivalents and restricted cash and cash equivalents at end of period | 283,042 | 241,070 | 179,256 | NaN |